Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.

International journal of cancer - 1 Mar 2020

Bellmann Lydia, Cappellano Giuseppe, Schachtl-Riess Johanna F, Prokopi Anastasia, Seretis Athanasios, Ortner Daniela, Tripp Christoph H, Brinckerhoff Constance E, Mullins David W, Stoitzner Patrizia

Abstract excerpt

Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. Observations from preclinical mouse models and recent insights into the immunological effects caused by BRAFi give promise for future development of combination therapy for human melanoma. In our study, we used the transplantable D4M melanoma mouse model with the BRAFV600E mutation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Evaluation, Preclinical
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma, Experimental

Share to Natural Killer T-Cells

Share to Sulfonamides

Share to Toll-Like Receptor 7

Source

Open in PubMed Open full text

Identifiers

PMID: 31702822
DOI: 10.1002/ijc.32777
PMCID: PMC7003881

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.PMID 31702822Read ↗

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.Semantic proximity Read ↗

Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma.Semantic proximity Read ↗

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.Semantic proximity Read ↗

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?Semantic proximity Read ↗

The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.Semantic proximity Read ↗

Targeting BRAFV600E in an inducible murine model of melanoma.Semantic proximity Read ↗

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.Semantic proximity Read ↗

T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Semantic proximity Read ↗

CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant MelanomaSemantic proximity Read ↗

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.Semantic proximity Read ↗

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.